Table 3.
Effects of sub-chronic treatment with different doses of edaravone on the incidences of tonic seizure and mortality in intraperitoneal PTZ-induced model of seizure
| Groups (n=6) | Tonic seizure protection (%) | P value | Mortality protection (%) | P value |
|---|---|---|---|---|
| Vehicle | 44.42 | 44.42 | ||
| Edaravone (5 mg/Kg) | 48.11 | 0.15a | 48.11 | 0.15a |
| Edaravone (7.5 mg/Kg) | 85.71* | 0.05a | 85.71* | 0.05a |
| Edaravone (10 mg/Kg) | 85.73* | 0.05a | 85.73* | 0.05a |
Percentages of the protections against the incidences of tonic seizure and mortality subsequent to intraperitoneal injections of PTZ (85 mg/Kg) were compared between the studied groups using the Chi square test.
a
The group was compared with the vehicle group. *P≤0.05 was considered significant.